Status:
COMPLETED
Leukocyte Function in Asthma and COPD
Lead Sponsor:
Imperial College London
Conditions:
Asthma
COPD
Eligibility:
All Genders
21-70 years
Brief Summary
The aim of this study is to examine the inflammatory mechanisms involved in the pathogenesis of inflammatory lung disease, in particular to compare the inflammatory profile seen in asthma and COPD. Ev...
Detailed Description
Overall subjects will be characterised into one of four groups: normal non-smoking subjects, healthy smokers, patients with asthma and patients with COPD. Subjects will have had to fulfil inclusion an...
Eligibility Criteria
Inclusion
- Asthmatic patients:
- Age 21-79 years of both sexes (females will be taking adequate contraceptive measures).
- Increase in FEV1 \>15% and \>200ml following beta2 agonist inhalation, either at the time of study or previously documented
- COPD patients:
- Stable patients with a post-salbutamol FEV1 30-70% predicted normal of \>1L
- Increase in FEV1 \< 15% and \< 200 ml following beta2 agonist inhalation, either at the time of study or previously documented
- Age 21-79 years of both sexes (females will be taking adequate contraceptive measures )
- Smokers
- No history of allergic or respiratory disease.
- Normal Volunteers
- Age 21-79 years of both sexes (females will be taking adequate contraceptive measures )
- Non-smokers
- Normal lung function
- No upper respiratory tract infection within the last 4 weeks
- No history of allergic or respiratory disease.
- Healthy Smokers 1. Age 21-79 years of both sexes (females will be taking adequate contraceptive measures ) 2. Smokers 3. Normal lung function 4. No upper respiratory tract infection within the last 4 weeks
- \-
Exclusion
- Asthmatic patients with FEV1 less than 40% predicted value
- Alcohol abuse
- Any history or evidence of hepatic, cardiovascular or renal disease
- Any history or evidence of neuropsychiatric disease
- Drug abuse or any other condition associated with poor compliance
- Pregnancy or breast feeding
- Patients are unable to provide written informed consent
- COPD patients:
- 1\. Any other active lung diseases 2. Upper respiratory infection within the last 4 weeks 3. Pregnancy or breast feeding 4. Any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study 5. Subjects unable to give informed consent
- \-
Key Trial Info
Start Date :
April 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00147069
Start Date
April 1 2004
End Date
April 1 2007
Last Update
December 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton Hospital/NHLI Imperial College London
London, United Kingdom, SW3 6LY